Curis Inc. reports biotechnology developments centered on emavusertib (CA-4948), an orally available small-molecule IRAK4 and FLT3 inhibitor. Company updates focus on oncology programs in lymphoma, chronic lymphocytic leukemia and acute myeloid leukemia, including clinical data presentations, combination approaches with BTK inhibitors, and studies involving venetoclax and azacitidine.
Recurring Curis news also covers quarterly financial and operating results, conference-call updates, capital actions such as private placements, and security-structure matters involving preferred stock and warrants. The company’s public updates combine clinical-program progress with financing, governance and operating disclosures typical of a development-stage biotechnology issuer.
Curis, Inc. (NASDAQ: CRIS) will announce its second quarter 2020 financial results on August 4, 2020, after US market close. A conference call is scheduled for the same day at 4:30 p.m. ET, accessible via phone or the company's website. Curis specializes in developing innovative therapeutics for cancer treatment and has ongoing collaborations focusing on immuno-oncology and precision oncology. The company holds exclusive licenses for several drug candidates currently in clinical trials.